[1] Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review [J]. Adv Ther, 2021, 38(1): 180-200. DOI: 10.1007/s12325-020-01568-8.
[2] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6.
[3] Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016 [J]. Kidney Int, 2018, 94(3): 567-581. DOI: 10.1016/j.kint.2018.04.011.
[4] Parker K, Bull-Engelstad I, Aasebø W, et al. Medication regimen complexity and medication adherence in elderly patients with chronic kidney disease [J]. Hemodial Int, 2019, 23(3):333-342. DOI:10.1111/hdi.12739.
[5] Magacho EJC, Ribeiro LC, Chaoubah A, et al. Adherence to drug therapy in kidney disease [J]. Braz J Med Biol Res, 2011, 44: 258-262. DOI: 10.1590/1806-9282.66.S1.31.
[6] Hsu KL, Fink JC, Ginsberg JS, et al. Self-reported medication adherence and adverse patient safety events in CKD [J]. Am J Kidney Dis, 2015, 66: 621-629. DOI: 10.1053/j.ajkd.2015.03.026.
[7] Tesfaye WH, McKercher C, Peterson GM, et al. Medication adherence, burden and health-related quality of life in adults with predialysis chronic kidney disease: a prospective cohort study [J]. Int J Environ Res Public Health, 2020, 17(1): 371. DOI: 10.3390/ijerph17010371.
[8] Shin J, Chia YC, Heo R, et al. Current status of adherence interventions in hypertension management in Asian countries: a report from the HOPE Asia Network [J]. J Clin Hypertens (Greenwich), 2020, 23(3):584-594. DOI: 10.1111/jch.14104.
[9] 孙振球,徐勇勇. 医学统计学[M]. 北京:人民卫生出版社,2014:524-525.
[10] Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of amedication adherence measure in an outpatient setting [J]. J Clin Hypertens, 2008, 10:348-354. DOI: 10.1111/j.1751-7176.2008.07572.x.
[11] Yang A, Wang B, Zhu G, et al. Validation of Chinese version of the Morisky Medication Adherence Scale in patients with epilepsy [J]. Seizure, 2014, 23:295-299. DOI: 10.1016/j.seizure.2014.01.003.
[12] Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication [J]. Psychol Health, 1999, 14:1-24. DOI: 10.1186/s12913-016-1423-5.
[13] Bai HH, Nie XJ, Chen XL, et al. Beliefs about medication and their association with adherence in Chinese patients with non-dialysis chronic kidney disease stages 3-5 [J]. Medicine (Baltimore), 2022, 101(2): e28491. DOI: 10.1097/MD.0000000000028491.
[14] Zimet GD, Powell SS, Farley GK, et al. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support [J]. J Pers Assess, 1990, 55(3-4): 610-617. DOI: 10.1080/00223891.1990.9674095.
[15] Zhou K, Li H, Wei X, et al. Reliability and validity of the multidimensional scale of perceived social support in Chinese mainland patients with methadone maintenance treatment [J]. Compr Psychiatry, 2015, 60:182-188. DOI: 10.1016/j.comppsych.2015.03.007.
[16] Zigmond AS, Snaith RP. The hospital anxiety and depression scale [J]. Acta Psychiatr Scand, 1983, 67(6): 361-370. DOI: 10.1016/s0022-3999(96)00216-4.
[17] Wang W, Chair SY, Thompson DR, et al. A psychometric evaluation of the Chinese version of the Hospital Anxiety and Depression Scale in patients with coronary heart disease [J]. J Clin Nurs, 2009, 18(13):1908-1915. DOI: 10.1111/j.1365-2702.2009.03043.x.
[18] Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens [J]. Cardiol Rev, 2007, 15(5):257-263. DOI: 10.1097/CRD.0b013e3180cabbe7.
[19] Burnier M, Pruijm M, Wuerzner G, et al. Drug adherence in chronic kidney diseases and dialysis [J]. Nephrol Dial Transplant, 2015, 30(1): 39-44. DOI: 10.1093/ndt/gfu015.
[20] Schmitt KE, Edie CF, Laflam P, et al. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease [J]. Am J Nephrol, 2010, 32(6):541-548. DOI: 10.1159/000321688.
[21] Sommer J, Seeling A, Rupprecht H. Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy [J]. Drugs Aging, 2020, 37(5): 359-372. DOI: 10.1007/s40266-020-00747-0.
[22] Campoy S, Elwell R. Pharmacology & CKD: how chronic kidney disease and its complications alter drug response [J]. Am J Nurs, 2005, 105(9): 60-72. DOI: 10.1097/00000446-200509000-00029.
[23] 丁兰, 林梅, 张清, 等.糖尿病肾病患者家庭照顾者照顾活动和支持行为现状的调查分析[J]. 中华现代护理杂志, 2021, 27(22): 2981-2987. DOI: 10.3760/cma.j.cn115682- 20201021-05843.
[24] 魏妃苑, 郭军军, 谷娟, 等. 慢性肾脏病患者科普健康信息需求调查及分析[J]. 国际医药卫生导报, 2022, 28(8): 1052-1057. DOI: 10.3760/cma.j.issn.1007-1245. 2022.08.004.
[25] Wong KK, Velasquez A, Powe NR, et al. Association between health literacy and self-care behaviors among patients with chronic kidney disease [J]. BMC Nephrology, 2018, 19: 196. DOI: 10.1186/s12882-018-0988-0.
[26] Goh ZS, Griva K. Anxiety and depression in patients with end-stage renal disease: impact and management challenges - a narrative review [J]. Int J Nephrol Renovasc Dis, 2018, 11:93-102. DOI: 10.2147/IJNRD.S126615.
[27] Han B, Yan B, Zhang J, et al. The influence of the social support on symptoms of anxiety and depression among patients with silicosis [J]. Scientific World Journal, 2014: 724804. DOI: 10.1155/2014/724804.
|